To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up;
Aged 18-75 years old (including 18 and 75 years old)
male or female
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Participants had a second primary malignancy detected prior to the first dose of study treatment, or has other malignancies diagnosed within 5 years prior to the first dose of study treatment, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ;
Allergy to study medication or excipients
With dysphagia or known malabsorption of drugs
Have participated in any other drug clinical trial and received the corresponding trial drug within the previous 4 weeks. Or are participating in other clinical studies that may interfere with this study.